News 18.10.2024 Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast...
News 18.10.2024 Topadur Pharma AG, a Swiss clinical-stage biotechnology company, today announces the appointments of PD Dr. Matthias Schäfer as Chief Innovation Officer (CIO) and Prof. Dr. Jay Siegel as Chief Research Officer (CRO). Matthias Schäfer is a seasoned international leader, who uniquely combines management skills with in-depth experience in biomedical research from...
Events, Internal events
Event date: 23.10.2024
10.30h – 12.00h, Bio-Technopark, Auditorium, Wagistrasse 25, 8952 Schlieren
We are thrilled to announce our upcoming event at the Biotech Hub in Zurich!
Join us for an insightful and interactive session on the latest advancements in empathic AI within the life sciences. Discover how AI and data embodied in the agent LakeSAI,...
News 16.10.2024 Zurich, Switzerland - 14.10.2024 Neurimmune today announced that the U.S. Food and Drug Administration (FDA) has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a systemic, progressive and life-threatening disease caused by the deposition of...
News 15.10.2024 October 14, 2024 - Zurich, Switzerland InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues. The study tested the hepatotoxicity of 152 FDA-approved drugs,...